At a glance
- Originator Sanofi-Synthelabo
- Class Antidepressants; Antiparkinsonians
- Mechanism of Action Monoamine oxidase A inhibitors; Monoamine oxidase B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Major depressive disorder; Parkinson's disease
Most Recent Events
- 27 Aug 1999 Sanofi and Synthélabo have now merged to form Sanofi-Synthélabo
- 09 Dec 1998 Preclinical development for Depression in France (Unknown route)
- 09 Dec 1998 Preclinical development for Parkinson's disease in France (Unknown route)